Cargando…
Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin
In attempts to develop an orally applicable platinum-based drug, platinum(IV) drugs which exhibit higher in vivo stability compared to the platinum(II) drug cisplatin were formulated. The first such chemotherapeutic agent, namely satraplatin, failed to receive approval. In the present work, we check...
Autor principal: | Hamilton, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190551/ https://www.ncbi.nlm.nih.gov/pubmed/25006835 http://dx.doi.org/10.3390/cancers6031487 |
Ejemplares similares
-
Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells
por: Olszewski, Ulrike, et al.
Publicado: (2011) -
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
por: Olszewski, Ulrike, et al.
Publicado: (2009) -
In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
por: Klameth, Lukas, et al.
Publicado: (2017) -
Dibromidodimethyldipyridineplatinum(IV)
por: Kelly, Mairéad E., et al.
Publicado: (2008) -
Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)